# Tesamorelin Dosage: The Dose and Half-Life Used in Trials > Tesamorelin dosage in the trial record: 2 mg/day subcutaneous in the pivotal Phase 3 studies, the ~26-38 minute half-life, clearance, and route. Research framing only, every figure cited. The dose used in the studies, the route, and the short plasma half-life set against the sustained IGF-1 effect — described as study parameters, not instructions. ## Before the details This page reports the tesamorelin dose used in the published trials and how the drug moves through the body. It is a description of study parameters, not a how-to. The recurring number is 2 mg per day, given as a subcutaneous injection (under the skin of the abdomen). One quirk worth knowing up front: the peptide itself clears the blood within hours, but its downstream effect — raised IGF-1 — lasts across the whole day, which is why once-daily dosing works. No human-use recommendation is given or implied here. ## Daily dose used in the trials The studied dose is 2 mg subcutaneously once daily. That was the regimen in both pivotal Phase 3 trials and the FDA-approved dosing for the original approved formulations [1][2]. The JAMA hepatic-fat trial and the mechanistic study in healthy men used the same 2 mg/day subcutaneous dose [3][4]. A lower 1 mg/day arm appears in mechanistic and safety work, but the 2 mg/day once-daily paradigm is the extensively studied one [12]. The only route studied in clinical trials, and the only approved route, is subcutaneous injection at an abdominal site. These are the parameters administered in research; this site gives no human dosing instruction. ## Half-life and how long tesamorelin stays in the system Plasma exposure is short. Secondary sources (the FDA label and Mayo Clinic) describe a terminal half-life on the order of 26-38 minutes [13]. Population pharmacokinetic modeling reported an apparent plasma clearance of roughly 1,060 L/h with no clinically relevant demographic covariates [13]. Despite that rapid clearance, the downstream IGF-1 elevation persists across the dosing interval — which is the pharmacological basis for once-daily administration [13]. The peptide leaves the plasma quickly; its biological effect, mediated through growth hormone and IGF-1, outlasts the molecule itself. ## Stability and formulation The trans-3-hexenoic-acid N-terminal modification blocks the DPP-IV cleavage that rapidly inactivates native GHRH, which is what gives tesamorelin a usable duration of action [11]. The approved product is supplied as a lyophilized (freeze-dried) powder requiring reconstitution before subcutaneous injection; the label specifies refrigerated storage and use of the reconstituted solution within a defined window [13]. Research-grade material sold for laboratory use is a different thing from the approved finished drug product. It lacks the purity, potency, and stability oversight of the approved formulation, and the parameters above describe the studied clinical product. ## What is the half-life of tesamorelin? Plasma exposure is short. Secondary sources describe a terminal half-life of roughly 26-38 minutes; population PK modeling reported apparent clearance of about 1,060 L/h [13]. Despite rapid clearance, IGF-1 elevation persists across the dosing interval, supporting once-daily administration. ## How long does tesamorelin stay in your system? The peptide itself clears the plasma within hours (apparent clearance about 1,060 L/h) [13]. Its downstream effect — raised IGF-1 — persists across the once-daily dosing interval, so the biological signal outlasts the molecule's presence in the blood. --- Tesarx files the tesamorelin record as a flat, hard-bordered data sheet — every visceral-fat and IGF-1 figure logged straight to its study, the lone HIV-lipodystrophy approval and the off-label edge ruled in plain view; an exposed-document digest, never a clinic, a pharmacy, or a prescription.